Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
April 17, 2026Annals of HematologyOpen Access

Real-world effectiveness of zanubrutinib plus salvage chemotherapy in relapsed or refractory double-expressor DLBCL

View Full Paper
Ask AI
Bookmark
Share

Authors

JLJinbo LuYZYujie ZhangXYXuan Ye

Discussion

Loading...

Member takes

Overview

Retrospective analysis shows improved outcomes in relapsed or refractory double-expressor DLBCL, suggesting a viable treatment option.

Key Points

  • Evaluate the efficacy and safety of zanubrutinib with salvage chemotherapy for R/R DE-DLBCL.
  • Retrospective analysis of 35 patients treated at two centers.
  • Patients received zanubrutinib and various salvage regimens.
  • Endpoints included objective response rate, complete response rate, progression-free survival, overall survival, and adverse events.
  • Overall response rate was 45.7% and complete response rate was 42.9%.
  • Median progression-free survival was 8.0 months and overall survival was 12.0 months.
  • Relapsed patients had a higher complete response rate than refractory patients (56.5% vs. 16.7%).
  • Main grade 3–4 adverse events included neutropenia (42.8%) and thrombocytopenia (14.3%).

Cite This Study

Lu et al. (2026) studied this question.

synapsesocial.com/papers/69e1cdc45cdc762e9d857039https://doi.org/10.1007/s00277-026-06974-6
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Efficacy and safety of zanubrutinib combined with chemotherapy in the treatment of relapsed/refractory diffuse large B-cell lymphoma2025
  2. 2Phase 1 Study of Zanubrutinib Plus Lenalidomide in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma2026
  3. 3A phase 2 study of zanubrutinib in combination with rituximab and lenalidomide in de novo diffuse large B-cell lymphoma2025 · 7 citations
  4. 4A real-world multicenter study of first-line zanubrutinib-based therapy for diffuse large B-cell lymphoma2026
  5. 5Zanubrutinib in combination with R-CHOP for previously untreated mcd type of Diffuse large b-cell lymphoma (DLBCL).2025